uric acid has been researched along with Nausea in 30 studies
Uric Acid: An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN.
uric acid : An oxopurine that is the final oxidation product of purine metabolism.
6-hydroxy-1H-purine-2,8(7H,9H)-dione : A tautomer of uric acid having oxo groups at C-2 and C-8 and a hydroxy group at C-6.
7,9-dihydro-1H-purine-2,6,8(3H)-trione : An oxopurine in which the purine ring is substituted by oxo groups at positions 2, 6, and 8.
Nausea: An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A dosage of 300 mg/d of allopurinol was not effective in reducing pain or improving activities of daily living in chronic pancreatitis." | 9.08 | Does allopurinol reduce pain of chronic pancreatitis? ( Banks, PA; Ferrante, M; Hughes, M; Noordhoek, EC; Ramagopal, V; Slivka, A, 1997) |
| "Thirty-one pediatric patients with acute leukemia who had relapsed on either 6-mercaptopurine or 6-thioguanine were treated with beta-2'-deoxythioguanosine, which was administered as an iv infusion every 12 hours for three or six doses every 2 weeks." | 7.67 | Phase I evaluation of beta-2'-deoxythioguanosine in pediatric patients with leukemia. ( Hartman, G; Higgins, GR; Jamin, DC; Momparler, R; Shore, NA; Siegel, SE, 1985) |
| "A dosage of 300 mg/d of allopurinol was not effective in reducing pain or improving activities of daily living in chronic pancreatitis." | 5.08 | Does allopurinol reduce pain of chronic pancreatitis? ( Banks, PA; Ferrante, M; Hughes, M; Noordhoek, EC; Ramagopal, V; Slivka, A, 1997) |
| "The presence of nausea and vomiting, epigastric pain, or both in association with admission laboratory values that are in excess of the cutoffs for lactate dehydrogenase, aspartate aminotransferase, and uric acid concentrations or for all 6 tests is predictive of high risk of morbidity for the patient with severe preeclampsia." | 3.70 | Early risk assessment of severe preeclampsia: admission battery of symptoms and laboratory tests to predict likelihood of subsequent significant maternal morbidity. ( Blake, PG; Magann, EF; Martin, JN; May, WL; Rinehart, BK; Terrone, DA, 1999) |
| "Thirty-one pediatric patients with acute leukemia who had relapsed on either 6-mercaptopurine or 6-thioguanine were treated with beta-2'-deoxythioguanosine, which was administered as an iv infusion every 12 hours for three or six doses every 2 weeks." | 3.67 | Phase I evaluation of beta-2'-deoxythioguanosine in pediatric patients with leukemia. ( Hartman, G; Higgins, GR; Jamin, DC; Momparler, R; Shore, NA; Siegel, SE, 1985) |
| "Long-term flexible dosing with colestilan reduces serum phosphorus and demonstrates an acceptable safety and tolerability profile." | 2.82 | Long-Term Evaluation of Colestilan in Chronic Kidney Disease Stage 5 Dialysis Patients with Hyperphosphataemia. ( Dimkovic, N; Locatelli, F; Spasovski, G; Wanner, C, 2016) |
| "Class 3 HELLP syndrome is considered a clinically significant transitional group." | 1.30 | The spectrum of severe preeclampsia: comparative analysis by HELLP (hemolysis, elevated liver enzyme levels, and low platelet count) syndrome classification. ( Blake, PG; Magann, EF; Martin, JN; May, WL; Rinehart, BK; Terrone, DA, 1999) |
| " How the adverse effects of and charges for this procedure compare with those of the standard marrow harvest is not known." | 1.29 | Clinical toxicity and laboratory effects of granulocyte-colony-stimulating factor (filgrastim) mobilization and blood stem cell apheresis from normal donors, and analysis of charges for the procedures. ( Anderlini, P; Champlin, R; Chan, KW; Körbling, M; Lichtiger, B; Miller, P; Norfleet, F; Przepiorka, D; Seong, D; Sundberg, J, 1996) |
| "Tiazofurin is a novel C-nucleoside with significant antitumor activity in murine tumor models." | 1.27 | Phase I trial of tiazofurin administered by i.v. bolus daily for 5 days, with pharmacokinetic evaluation. ( Culham, CA; Hartshorn, JN; Haugh, LD; Krakoff, IR; McCormack, JJ; Newman, RA; Roberts, JD; Stewart, JA; Young, JA, 1987) |
| "Azosemide is a new loop diuretic which has been shown to affect solute transport proximal to the diluting segment." | 1.26 | Effects in normal subjects of long-term administration of azosemide. ( Anderson, S; Brater, C; Muckleroy, C, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 24 (80.00) | 18.7374 |
| 1990's | 4 (13.33) | 18.2507 |
| 2000's | 1 (3.33) | 29.6817 |
| 2010's | 1 (3.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Locatelli, F | 1 |
| Spasovski, G | 1 |
| Dimkovic, N | 1 |
| Wanner, C | 1 |
| Shils, ME | 1 |
| Emmerson, BT | 1 |
| Neyer, U | 1 |
| Wöss, E | 1 |
| Haller, R | 1 |
| Kröss, R | 1 |
| Smyth, JF | 1 |
| Paine, RM | 1 |
| Jackman, AL | 1 |
| Harrap, KR | 1 |
| Chassin, MM | 1 |
| Adamson, RH | 1 |
| Johns, DG | 1 |
| Anderlini, P | 1 |
| Przepiorka, D | 1 |
| Seong, D | 1 |
| Miller, P | 1 |
| Sundberg, J | 1 |
| Lichtiger, B | 1 |
| Norfleet, F | 1 |
| Chan, KW | 1 |
| Champlin, R | 1 |
| Körbling, M | 1 |
| Banks, PA | 1 |
| Hughes, M | 1 |
| Ferrante, M | 1 |
| Noordhoek, EC | 1 |
| Ramagopal, V | 1 |
| Slivka, A | 1 |
| Martin, JN | 2 |
| Rinehart, BK | 2 |
| May, WL | 2 |
| Magann, EF | 2 |
| Terrone, DA | 2 |
| Blake, PG | 2 |
| Carducci, MA | 1 |
| Gilbert, J | 1 |
| Bowling, MK | 1 |
| Noe, D | 1 |
| Eisenberger, MA | 1 |
| Sinibaldi, V | 1 |
| Zabelina, Y | 1 |
| Chen, TL | 1 |
| Grochow, LB | 1 |
| Donehower, RC | 1 |
| Brater, C | 1 |
| Anderson, S | 1 |
| Muckleroy, C | 1 |
| Merrin, C | 1 |
| Matzkies, F | 2 |
| Hirschel, B | 1 |
| Bosl, R | 1 |
| Shideman, JR | 1 |
| Meyer, RM | 1 |
| Buselmeier, TJ | 1 |
| von Hartitzsch, B | 1 |
| Kjellstrand, CM | 1 |
| Simonson, GM | 1 |
| Roberts, JD | 1 |
| Stewart, JA | 1 |
| McCormack, JJ | 1 |
| Krakoff, IR | 1 |
| Culham, CA | 1 |
| Hartshorn, JN | 1 |
| Newman, RA | 1 |
| Haugh, LD | 1 |
| Young, JA | 1 |
| Higgins, GR | 1 |
| Jamin, DC | 1 |
| Shore, NA | 1 |
| Momparler, R | 1 |
| Hartman, G | 1 |
| Siegel, SE | 1 |
| Dubiel, W | 1 |
| Happle, R | 1 |
| Berg, G | 1 |
| Bickel, H | 1 |
| Zeilhofer, R | 1 |
| Perheentupa, J | 1 |
| Raivio, KO | 1 |
| Nikkilä, EA | 1 |
| Hutchison, JC | 1 |
| Oettgen, HF | 1 |
| Stephenson, PA | 1 |
| Schwartz, MK | 1 |
| Leeper, RD | 1 |
| Tallai, L | 1 |
| Tan, CC | 1 |
| Clarkson, BD | 1 |
| Golbey, RB | 1 |
| Krakoff, IH | 1 |
| Karnofsky, DA | 1 |
| Murphy, ML | 1 |
| Burchenal, JH | 1 |
| Gifford, RW | 1 |
| Harvengt, C | 1 |
| Lavenne, F | 1 |
| Kennedy, CC | 1 |
| Spiekerman, RE | 1 |
| Elveback, L | 1 |
| Hartmann, G | 1 |
| Schmid, R | 1 |
| Storti, E | 1 |
| Quaglino, D | 1 |
| Barbeau, A | 1 |
| Mars, H | 1 |
| Gillo-Joffroy, L | 1 |
| Lawlor, T | 1 |
| Wells, DG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase III, Multi-center, Open Label, Flexible Dose, Long Term Safety Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia[NCT00772382] | Phase 3 | 116 participants (Actual) | Interventional | 2008-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00772382)
Timeframe: 52 weeks
| Intervention | mg/dL (Mean) |
|---|---|
| MCI-196 | -1.18 |
(NCT00772382)
Timeframe: 52 weeks
| Intervention | participants (Number) | ||
|---|---|---|---|
| At least 1 treatment-emergent AE | At least 1 drug-related treatment-emergent AE | At least 1 treatment-emergent serious AE | |
| MCI-196 | 109 | 50 | 63 |
1 review available for uric acid and Nausea
| Article | Year |
|---|---|
Hereditary fructose intolerance.
Topics: 17-Ketosteroids; Blood Glucose; Carbohydrate Metabolism, Inborn Errors; Child; Cholesterol; Diet The | 1972 |
8 trials available for uric acid and Nausea
| Article | Year |
|---|---|
Long-Term Evaluation of Colestilan in Chronic Kidney Disease Stage 5 Dialysis Patients with Hyperphosphataemia.
Topics: Adult; Aged; Bile Acids and Salts; Cholesterol, LDL; Diarrhea; Female; Glycated Hemoglobin; Hemodial | 2016 |
Does allopurinol reduce pain of chronic pancreatitis?
Topics: Abdominal Pain; Activities of Daily Living; Adult; Allopurinol; Ankle; Blood Cell Count; Chronic Dis | 1997 |
A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule.
Topics: Adult; Antineoplastic Agents; Chromatography, High Pressure Liquid; Disorders of Excessive Somnolenc | 2001 |
[Experimental treatment with fumaric acid monoethylester in psoriasis vulgaris].
Topics: Administration, Oral; Adult; Blood Urea Nitrogen; Clinical Trials as Topic; Creatinine; Drug Eruptio | 1972 |
The hypotensive action of ethacrynic acid.
Topics: Abdomen; Adult; Aged; Antihypertensive Agents; Black People; Blood Glucose; Blood Pressure Determina | 1968 |
Ethacrynic acid alone and in combination with methyldopa in the management of mild hypertension. A report of 23 patients.
Topics: Adult; Aged; Blood Pressure; Clinical Trials as Topic; Diarrhea; Drug Synergism; Ethacrynic Acid; Fe | 1970 |
[Influence of aluminum nicotinate on serum lipids].
Topics: Adult; Alkaline Phosphatase; Aluminum; Arteriosclerosis; Blood Glucose; Cardiovascular Diseases; Cho | 1969 |
Antihypertensive properties of cryptenamine used with reserpine and methyclothiazide.
Topics: Adult; Aged; Anorexia Nervosa; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Weight; | 1971 |
21 other studies available for uric acid and Nausea
| Article | Year |
|---|---|
EXPERIMENTAL HUMAN MAGNESIUM DEPLETION. I. CLINICAL OBSERVATIONS AND BLOOD CHEMISTRY ALTERATIONS.
Topics: Biomedical Research; Blood Chemical Analysis; Calcium; Calcium, Dietary; Cholesterol; Electromyograp | 1964 |
Regimen of indomethacin therapy in acute gouty arthritis.
Topics: Adult; Creatine; Female; Gout; Headache; Humans; Indomethacin; Male; Middle Aged; Nausea; Urea; Uric | 1967 |
[Headache and EEG changes caused by acetate and bicarbonate dialysis].
Topics: Acetates; Acid-Base Equilibrium; Adult; Bicarbonates; Electroencephalography; Headache; Humans; Naus | 1983 |
The clinical pharmacology of the adenosine deaminase inhibitor 2'-deoxycoformycin.
Topics: Adenosine Deaminase Inhibitors; Adult; Aged; Animals; Coformycin; Dogs; Female; Humans; Kinetics; Le | 1980 |
Clinical toxicity and laboratory effects of granulocyte-colony-stimulating factor (filgrastim) mobilization and blood stem cell apheresis from normal donors, and analysis of charges for the procedures.
Topics: Adolescent; Adult; Alkaline Phosphatase; Analgesics; Blood Transfusion, Autologous; Bone Marrow Tran | 1996 |
The spectrum of severe preeclampsia: comparative analysis by HELLP (hemolysis, elevated liver enzyme levels, and low platelet count) syndrome classification.
Topics: Aspartate Aminotransferases; Birth Weight; Cesarean Section; Eclampsia; Female; Fetal Death; Headach | 1999 |
Early risk assessment of severe preeclampsia: admission battery of symptoms and laboratory tests to predict likelihood of subsequent significant maternal morbidity.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Creatinine; Female; HELLP Syndrome; Humans; L-Lac | 1999 |
Effects in normal subjects of long-term administration of azosemide.
Topics: Diet, Sodium-Restricted; Diuretics; Drug Evaluation; Headache; Humans; Nausea; Potassium; Renin; Sod | 1979 |
Treatment of advanced bladder cancer with cis-diamminedichloroplatinum (II NSC 119875): a pilot study.
Topics: Carcinoma, Transitional Cell; Cisplatin; Female; Humans; Leukopenia; Male; Nausea; Neoplasm Metastas | 1978 |
[Effects and side effects of benzbromaron in the initial treatment of hyperuricemia and gout. Results of a field study on 3899 patients].
Topics: Benzbromarone; Benzofurans; Diarrhea; Female; Gout; Humans; Kidney Calculi; Male; Nausea; Uric Acid | 1978 |
[Dr. Atkins' dietetic revolution: a critique].
Topics: Acidosis; Adult; Cholesterol; Diet, Reducing; Dietary Carbohydrates; Dietary Fats; Energy Intake; Hu | 1977 |
Effects and complications of high efficiency dialysis.
Topics: Barbiturates; Blood Urea Nitrogen; Body Weight; Calcium; Creatinine; Edema; Headache; Humans; Hypote | 1975 |
Caring for patients with acute myelocytic leukemia.
Topics: Bone Marrow; Daunorubicin; Hematologic Diseases; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged | 1988 |
Phase I trial of tiazofurin administered by i.v. bolus daily for 5 days, with pharmacokinetic evaluation.
Topics: Adult; Aged; Allopurinol; Antimetabolites, Antineoplastic; Creatine Kinase; Drug Administration Sche | 1987 |
Phase I evaluation of beta-2'-deoxythioguanosine in pediatric patients with leukemia.
Topics: Acute Disease; Acute Kidney Injury; Child; Deoxyguanosine; Drug Evaluation; Humans; Leukemia; Leukem | 1985 |
[Acid-base equilibrium in long-term infusions of xylitol, fructose, glucose and carbohydrate mixtures].
Topics: Acid-Base Equilibrium; Adult; Bicarbonates; Blood; Carbon Dioxide; Carbonates; Chlorides; Drug Inter | 1973 |
Toxicity of E. coli L-asparaginase in man.
Topics: Adult; Agranulocytosis; Antigen-Antibody Reactions; Asparaginase; Blood Platelet Disorders; Bone Mar | 1970 |
[Prolonged fasting as a method of treating obesity].
Topics: Acid-Base Equilibrium; Aged; Coronary Disease; Diabetes Mellitus; Diabetic Ketoacidosis; Fasting; Fa | 1967 |
Dysmetabolic and neurological complications in leukemia patients treated with L-asparaginase.
Topics: Asparaginase; Central Nervous System Diseases; Child; Clinical Enzyme Tests; Drug Hypersensitivity; | 1970 |
Adverse clinical side effects of levodopa therapy.
Topics: Antiparkinson Agents; Arrhythmias, Cardiac; Benserazide; Carboxy-Lyases; Dihydroxyphenylalanine; Ede | 1971 |
Metabolic hazards of fasting.
Topics: Adult; Anemia; Autoanalysis; Blood Cell Count; Blood Proteins; Blood Urea Nitrogen; Body Weight; Chl | 1969 |